Search

Your search keyword '"Argnani, Lisa"' showing total 619 results
Start Over Author "Argnani, Lisa"
619 results on '"Argnani, Lisa"'

2. Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma

Author

Di Staso, Rossana, Casadei, Beatrice, Locke, Frederick L., Jain, Michael, Voorhees, Timothy J., Kittai, Adam S., Bastos-Oreiro, Mariana, Gutiérrez, Antonio, Martin Garcia-Sancho, Alejandro, Terol, Maria Jose, Mead, Monica, Maranzano, Michael J., Iacoboni, Gloria, Barba, Pere, Kwon, Mi, Bailen, Rebeca, Reguera-Ortega, Juan Luis, Mian, Agrima, Hill, Brian, Bachy, Emmanuel, Morschhauser, Franck, Houot, Roch, Thieblemont, Catherine, Le Gouill, Steven, Masetti, Riccardo, Gori, Davide, Broccoli, Alessandro, Zinzani, Pier Luigi, and Argnani, Lisa

Published
2024
Full Text
View/download PDF

7. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

Author

Alderuccio, Juan Pablo, Arcaini, Luca, Watkins, Marcus P., Beaven, Anne W., Shouse, Geoffrey, Epperla, Narendranath, Spina, Michele, Stefanovic, Alexandra, Sandoval-Sus, Jose, Torka, Pallawi, Alpert, Ash B., Olszewski, Adam J., Kim, Seo-Hyun, Hess, Brian, Gaballa, Sameh, Ayyappan, Sabarish, Castillo, Jorge J., Argnani, Lisa, Voorhees, Timothy J., Saba, Raya, Chowdhury, Sayan Mullick, Vargas, Fernando, Reis, Isildinha M., Kwon, Deukwoo, Alexander, Jonathan S., Zhao, Wei, Edwards, Dali, Martin, Peter, Cencini, Emanuele, Kamdar, Manali, Link, Brian K., Logothetis, Constantine N., Herrera, Alex F., Friedberg, Jonathan W., Kahl, Brad S., Luminari, Stefano, Zinzani, Pier Luigi, and Lossos, Izidore S.

Published
2022
Full Text
View/download PDF

8. Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma.

Author

Mazzoni, Camilla, Argnani, Lisa, Casadei, Beatrice, Broccoli, Alessandro, Gabrielli, Giulia, Fabbri, Nicole, Gugliotta, Gabriele, Pellegrini, Cinzia, Carella, Matteo, Bagnato, Gianmarco, Gentilini, Marianna, Morigi, Alice, Maglio, Pierluca, Cantelli, Martina, Stefoni, Vittorio, and Zinzani, Pier Luigi

Subjects
*MUCOSA-associated lymphoid tissue lymphoma, *HELICOBACTER pylori, *CANCER treatment, *RITUXIMAB, *DISEASE progression
Abstract

ABSTRACT First‐line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except for eradication therapy for Helicobacter pylori in early gastric MZL. Various regimens, for example, locoregional treatment and systemic chemo‐immunotherapy, can be used depending on the site and stage of disease. Single‐agent rituximab is a useful approach in the setting of localized, low‐intermediate risk EMZL. The aim our research was to analyze the effectiveness and safety of single‐agent rituximab (375 mg/m2 once weekly for 4 weeks) in naïve EMZL in a real‐life setting. The primary endpoint was the overall response rate (ORR), secondary endpoints were progression‐free (PFS), overall (OS) and disease‐free survivals (DFS), and drug tolerability. Fifty‐nine patients were analyzed. Median time between diagnosis and rituximab was 3.6 months. The ORR was 89.9%, with 67.8% complete response (CR). Median DFS and PFS were reached at 6.3 and 5.3 years, respectively. After a median follow‐up of 5 years, median OS was not reached. The most common adverse event was infusion reaction, reported in 28 cases, mainly during the first infusion and easily manageable. Single‐agent rituximab may represent a valid therapeutic option in the first‐line treatment of EMZL, at least for localized disease, with a favorable toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study.

Author

Casadei, Beatrice, Conti, Gabriele, Barone, Monica, Turroni, Silvia, Guadagnuolo, Serafina, Broccoli, Alessandro, Brigidi, Patrizia, Argnani, Lisa, and Zinzani, Pier Luigi

Subjects
IMMUNE checkpoint inhibitors, END of treatment, GUT microbiome, SURVIVAL rate, LYMPHOMAS
Abstract

Biomarkers for immune checkpoint inhibitors (ICIs) response and resistance include PD‐L1 expression and other environmental factors, among which the gut microbiome (GM) is gaining increasing interest especially in lymphomas. To explore the potential role of GM in this clinical issue, feces of 30 relapsed/refractory lymphoma (Hodgkin and primary mediastinal B‐cell lymphoma) patients undergoing ICIs were collected from start to end of treatment (EoT). GM was profiled through Illumina, that is, 16S rRNA sequencing, and subsequently processed through a bioinformatics pipeline. The overall response rate to ICIs was 30.5%, with no association between patients clinical characteristics and response/survival outcomes. Regarding GM, responder patients showed a peculiar significant enrichment of Lachnospira, while non‐responder ones showed higher presence of Enterobacteriaceae (at baseline and maintained till EoT). Recognizing patient‐related factors that may influence response to ICIs is becoming critical to optimize the treatment pathway of heavily pretreated, young patients with a potentially long‐life expectancy. These preliminary results indicate potential early GM signatures of ICIs response in lymphoma, which could pave the way for future research to improve patients prognosis with new adjuvant strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation.

Author

Broccoli, Alessandro, Argnani, Lisa, Gugliotta, Gabriele, Pellegrini, Cinzia, Casadei, Beatrice, Bagnato, Gianmarco, Gentilini, Marianna, Stefoni, Vittorio, and Zinzani, Pier Luigi

Subjects
STEM cell transplantation, MEDICAL protocols, RESEARCH funding, RITUXIMAB, DESCRIPTIVE statistics, RETROSPECTIVE studies, MANN Whitney U Test, KAPLAN-Meier estimator, LOG-rank test, DATA analysis software, B cell lymphoma, ADULTS
Abstract

Introduction Intensive treatment approaches are required for adult patients with Burkitt lymphoma (BL), although an univocal standard of care still does not exist. The use of frontline autologous stem cells transplantation (ASCT) is debated. Patients and Methods Between 2004 and 2020, 50 patients with BL were treated with the Berlin-Frankfurt-Münster (BFM). Treatment plan consisted of 3 blocks, A (ifosfamide, vincristine, methotrexate, etoposide, and cytarabine), B (vincristine, cyclophosphamide, methotrexate, and doxorubicin), and C (vindesine, methotrexate, etoposide, and cytarabine), each repeated twice, every 28 days. Rituximab was given at day 1 each block. Intrathecal prophylaxis was given once per each block. ASCT was scheduled at the end of the 6 blocks after conditioning. Results Median age at onset was 38 years (range 16-72); stages III-IV disease was observed in 82% of cases; bulky disease occurred in 44% of the patients, with B-symptoms in 38%. Stem cell harvest was performed in 72% of patients, who all received a subsequent ASCT. The full 6 blocks treatment was completed in 70% of the patients. The overall response rate was 74%, with a complete response rate of 60%. Ten-year overall survival and progression-free survival were 83.7% and 76.0%, respectively, without reaching the median. Ten-year disease-free survival was 80.3%. Grades 3-4 neutropenia, thrombocytopenia, anemia, and mucositis were seen in 96%, 60%, 32%, and 24% of patients. Infections occurred in 60% of patients. Conclusion Intensive treatment according to BFM protocol, with rituximab and ASCT, appears feasible, safe, and highly effective in adult patients with BL, as confirmed by long-term survival rates reflecting response maintenance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Diffuse large B cell lymphoma characteristics and outcomes during the COVID-19 pandemic in two tertiary centers - an Israeli/ Italian study

Author

Giladi, Odil, primary, Bagnato, Gianmarco, additional, Gentilini, Marianna, additional, Shimony, Shai, additional, Pasvolsky, Oren, additional, Berger, Tamar, additional, Itchaki, Gilad, additional, Raanani, Pia, additional, Lolli, Ginerva, additional, Stefoni, Vittorio, additional, Broccoli, Alessandro, additional, Argnani, Lisa, additional, Zinzani, Pier Luigi, additional, and Gurion, Ronit, additional

Published
2023
Full Text
View/download PDF

19. P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE

Author

Rusconi, Chiara, primary, Ricci, Francesca, additional, Daffini, Rosa, additional, Casadei, Beatrice, additional, Ruggero Zilioli, Vittorio, additional, Mazzon, Federico, additional, Marasco, Vincenzo, additional, Calabretta, Eleonora, additional, Pagani, Chiara, additional, Argnani, Lisa, additional, Muzi, Cristina, additional, Guidetti, Anna, additional, Rodari, Marcello, additional, Passi, Angela, additional, Iadecola, Sara, additional, Cairoli, Roberto, additional, Luigi Zinzani, Pier, additional, Re, Alessandro, additional, Corradini, Paolo, additional, and Santoro, Armando, additional

Published
2023
Full Text
View/download PDF

20. Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report.

Author

Zoli, Sabrina, Pellegrini, Cinzia, Casadei, Beatrice, Broccoli, Alessandro, Argnani, Lisa, Nanni, Laura, Stefoni, Vittorio, and Zinzani, Pier Luigi

Subjects
DIFFUSE large B-cell lymphomas, LENALIDOMIDE
Abstract

Introduction: For primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT), there are no uniform recommendations for second-line treatment in case of relapse. Case Presentation: Here, we present the case of an elderly relapsed/refractory PCDLBCL-LT patient who obtained a prolonged clinical complete remission with lenalidomide. Conclusion: Lenalidomide as single agent led to an unexpected long complete response with manageable toxicity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma.

Author

Lolli, Ginevra, Argnani, Lisa, Gini, Guido, Casadei, Beatrice, Pellegrini, Cinzia, Tani, Monica, Pavone, Vincenzo, Cimminiello, Michele, Bonifazi, Francesca, and Zinzani, Pier Luigi

Subjects
DIFFUSE large B-cell lymphomas, HISTOCOMPATIBILITY antigens, CHIMERIC antigen receptors, T cells, STEM cell transplantation
Abstract

This article discusses the use of pixantrone as a bridging therapy (BT) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are undergoing chimeric antigen receptor (CAR) T-cell therapy or allogeneic stem cell transplantation (allo-SCT). Pixantrone is a drug with low cardiotoxic potential and few side effects. The study, conducted in Italy, collected data from 13 patients who received pixantrone as BT. The results showed that pixantrone effectively controlled lymphoma-related symptoms and allowed patients to proceed with subsequent planned therapy. The overall response rate (ORR) was 23% after pixantrone, and the ORR after CAR T-cell therapy or allo-SCT was 76.9%. Adverse events were limited, and no cardiotoxicities were reported. The median overall survival was 10.5 months, and the median progression-free survival was 5.2 months. The authors recommend considering pixantrone as a valid and widely available option for bridging therapy in DLBCL patients. [Extracted from the article]

Published
2023
Full Text
View/download PDF

22. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study

Author

Agostinelli, Claudio, Gallamini, Andrea, Stracqualursi, Luisa, Agati, Patrizia, Tripodo, Claudio, Fuligni, Fabio, Sista, Maria Teresa, Fanti, Stefano, Biggi, Alberto, Vitolo, Umberto, Rigacci, Luigi, Merli, Francesco, Patti, Caterina, Romano, Alessandra, Levis, Alessandro, Trentin, Livio, Stelitano, Caterina, Borra, Anna, Piccaluga, Pier Paolo, Hamilton-Dutoit, Stephen, Kamper, Peter, Zaucha, Jan Maciej, Małkowski, Bogdan, Kulikowski, Waldemar, Tajer, Joanna, Subocz, Edyta, Rybka, Justyna, Steidl, Christian, Broccoli, Alessandro, Argnani, Lisa, Gascoyne, Randy D, d'Amore, Francesco, Zinzani, Pier Luigi, and Pileri, Stefano A

Published
2016
Full Text
View/download PDF

25. Cost‐Effectiveness of the Early Arthritis Clinic Organizational Model

Author

Zanetti, Anna, primary, Sakellariou, Garifallia, additional, Zambon, Antonella, additional, Carrara, Greta, additional, Argnani, Lisa, additional, Mantovani, Lorenzo G., additional, Cortesi, Paolo A., additional, Bugatti, Serena, additional, Montecucco, Carlomaurizio, additional, and Scirè, Carlo A., additional

Published
2022
Full Text
View/download PDF

26. Rituximab As an Effective Salvage Therapy in Pretreated Hairy Cell Leukemia Patients: The Bologna Experience

Author

Broccoli, Alessandro, primary, Argnani, Lisa, additional, Nanni, Laura, additional, Bagnato, Gianmarco, additional, Carella, Matteo, additional, Casadei, Beatrice, additional, Coppola, Paolo Elia, additional, Gugliotta, Gabriele, additional, Lolli, Ginevra, additional, Gentilini, Marianna, additional, Morigi, Alice, additional, Pellegrini, Cinzia, additional, Stefoni, Vittorio, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

27. Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling

Author

Nanni, Laura, primary, Musuraca, Gerardo, additional, Morigi, Alice, additional, Stefoni, Vittorio, additional, Barone, Monica, additional, Conti, Gabriele, additional, Fabbrini, Marco, additional, Turroni, Silvia, additional, Broccoli, Alessandro, additional, Argnani, Lisa, additional, Brigidi, Patrizia, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

28. Critical Role of Hodgkin Lymphoma Cells-Derived Large and Small Extracellular Vesicles in the Regulation of the Immune-Inflammatory Microenvironment

Author

Maltoni, Filippo, primary, Ciardiello, Chiara, additional, Nanni, Laura, additional, Barone, Martina, additional, Narimanfar, Ghazal, additional, Casadei, Beatrice, additional, Argnani, Lisa, additional, Broccoli, Alessandro, additional, Forte, Dorian, additional, Budillon, Alfredo, additional, Zinzani, Pier Luigi, additional, and Catani, Lucia, additional

Published
2022
Full Text
View/download PDF

29. Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

Author

Argnani, Lisa, primary, Broccoli, Alessandro, additional, Pellegrini, Cinzia, additional, Fabbri, Alberto, additional, Puccini, Benedetta, additional, Bruna, Riccardo, additional, Tisi, Maria Chiara, additional, Masia, Francesco, additional, Flenghi, Leonardo, additional, Nizzoli, Maria Elena, additional, Musso, Maurizio, additional, Salerno, Marilena, additional, Scalzulli, Potito Rosario, additional, Dessi’, Daniela, additional, Ferrarini, Isacco, additional, Pennese, Elsa, additional, Lucchini, Elisa, additional, Rossi, Francesca Gaia, additional, Minoia, Carla, additional, Gherlinzoni, Filippo, additional, Musto, Pellegrino, additional, Patti, Caterina, additional, Stefoni, Vittorio, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

30. Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study

Author

Giladi, Odil, primary, Bagnato, Gianmarco, additional, Gentilini, Marianna, additional, Shimony, Shai, additional, Pasvolsky, Oren, additional, Berger, Tamar, additional, Itchaki, Gilad, additional, Raanani, Pia, additional, Broccoli, Alessandro, additional, Stefoni, Vittorio Stefoni, additional, Lolli, Ginevra, additional, Argnani, Lisa, additional, Zinzani, Pier Luigi, additional, and Gurion, Ronit, additional

Published
2022
Full Text
View/download PDF

31. A 3-decade multicenter European experience with cladribine as upfront treatment in 384 hairy cell leukemia patients

Author

Broccoli, Alessandro, Argnani, Lisa, Cross, Matthew, Janus, Agnieszka, Maitre, Elsa, Troussard, Xavier, Robak, Tadeusz, Dearden, Claire, Else, Monica, Catovsky, Daniel, Zinzani, Pier Luigi, Broccoli, Alessandro, Argnani, Lisa, Cross, Matthew, Janus, Agnieszka, Maitre, Elsa, Troussard, Xavier, Robak, Tadeusz, Dearden, Claire, Else, Monica, Catovsky, Daniel, and Zinzani, Pier Luigi

Subjects
Cladribine, up-front treatment, hairy cell leukemia
Abstract

Cladribine is regarded as the first treatment of choice of symptomatic hairy cell leukemia (HCL): it provides high rates of response and very long duration of remission in some cases. Disease-specific patients records have been reviewed at four European centers of excellence; all patients with HCL requiring treatment who received frontline cladribine have been extrapolated. Responses have been classified according to Consensus Resolution Criteria. Three hundred and eighty-four patients have been diagnosed and followed between 1969 and 2018; all received frontline cladribine (subcutaneously or intravenously). A complete response was obtained in 72% of cases and a partial response in 22%. A continuous complete response was documented in 20% of patients at a median follow-up period of 8.5 years (range, 1-22 years). Median overall survival was reached at 25 years. Median progression-free survival was 13 years and median disease-free survival was 11 years. Cladribine is effective as frontline treatment of HCL and may determine deep disease control in a significant proportion of cases, given that more than 50% of treated patients require no further therapy. Good quality responses may be maintained for more than 20 years in up to 35% of patients.

Published
2022

37. Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series

Author

Broccoli, Alessandro, primary, Argnani, Lisa, additional, Coppola, Paolo Elia, additional, Gentilini, Marianna, additional, Bagnato, Gianmarco, additional, Lolli, Ginevra, additional, Carella, Matteo, additional, Nanni, Laura, additional, Morigi, Alice, additional, Casadei, Beatrice, additional, Pellegrini, Cinzia, additional, Stefoni, Vittorio, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

42. Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study

Author

Casadei, Beatrice, primary, Argnani, Lisa, additional, Broccoli, Alessandro, additional, Patti, Caterina, additional, Stefani, Piero Maria, additional, Cuneo, Antonio, additional, Margiotta Casaluci, Gloria, additional, Visco, Carlo, additional, Gini, Guido, additional, Pane, Fabrizio, additional, D’Alò, Francesco, additional, Luzi, Debora, additional, Cantonetti, Maria, additional, Pozzi, Samantha, additional, Musuraca, Gerardo, additional, Rosignoli, Chiara, additional, Arcari, Annalisa, additional, Kovalchuk, Sofya, additional, Tani, Monica, additional, Tisi, Maria Chiara, additional, Petrini, Mario, additional, Stefoni, Vittorio, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

50. Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS

Author

Stefoni, Vittorio, Marangon, Miriam, Re, Alessandro, Lleshi, Arben, Bonfichi, Maurizio, Pinto, Antonello, Bianchetti, Nicola, Pellegrini, Cinzia, Argnani, Lisa, Zinzani, Pier Luigi, Stefoni, Vittorio, Marangon, Miriam, Re, Alessandro, Lleshi, Arben, Bonfichi, Maurizio, Pinto, Antonello, Bianchetti, Nicola, Pellegrini, Cinzia, Argnani, Lisa, and Zinzani, Pier Luigi

Subjects
brentuximab vedotin, Hodgkin's Lymphoma, Cell Therapy and Immunotherapy, elderly
Abstract

NA

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results